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Abstract: Atypical ﬁ  broxanthoma (AFX) is a nodular dermal ulcerative lesion with a favorable prognosis. AFX most 
commonly occurs on sun-exposed skin in elderly individuals. AFX is characterized by its association with ultraviolet 
radiation, not only from a clinical aspect, but also from a molecular aspect. Making a diagnosis of AFX is challenging, and 
it is important to differentiate it from squamous cell carcinoma and malignant melanoma. Histological features and combined 
immunohistochemical markers are necessary for a deﬁ  nitive diagnosis (i.e., an absence of immunostaining for cytokeratins, 
S100 and HMB45 in AFX is helpful for excluding both squamous cell carcinoma and malignant melanoma). AFX, as well 
as MFH (malignant ﬁ  brous histiocytoma), is a ﬁ  brohistiocytic lesion with myoﬁ  broblastic differentiation. AFX is considered 
to be a different lesion from MFH. AFX and MFH might share the same pathway which determines their morphology. 
However, they may have different pathways in development which determine their biological behavior.
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Introduction
History
The term, “atypical ﬁ  broxanthoma (AFX) ”, was proposed by Helwig in 1963 for a lesion that was 
considered to demonstrate a reactive process (Helwig EB, 1963). This led to the establishment of the 
distinct clinicopathological features of AFX (Fretzin DF and Helwig EB, 1973).
Clinical features
AFX has been described in two clinical settings. More commonly, the tumor occurs on sun-exposed 
skin in elderly individuals. The majority of tumors are on the scalp, face, ears and upper limbs (Mirza 
B and Weedon D, 2005). In its less common form, the tumor occurs on the limbs and trunk when there 
is a lack of association with sun exposure in young individuals (Dahl I, 1976). Interestingly, AFX 
develops in organ transplant recipients who may be in a state of immunosuppression (Hafner J et al. 
1999; Kanitakis J et al. 1996; Paquet P and Pierard GE, 1996). There have been rare reports of cases 
of multiple tumors (Mirza B and Weedon D, 2005; Nadjem MA et al. 1988). Furthermore, it has been 
reported that there is a predominance in men (70% men; 30% women). The average age is reported to 
be 71.9 years, ranging from 29–91 years (Mirza B and Weedon D, 2005).
Histological features
AFX is a nodular dermal ulcerative lesion which typically shows rapid growth (Fig. 1). The color of 
AFX varies from tan to light-brown. The size is usually less than 2 cm in diameter (Enzinger FM and 
Weiss SW, 2001; Fretzin DF and Helwig EB, 1973) and the average preoperative size has been reported 
to be 1.7 cm (Seavolt M and McCall M, 2006). About half the cases are ulcerated (Mirza B and Weedon 
D, 2005) (Fig. 2).
AFX is composed of spindle, plump, epithelioid and bizarre cells, in various proportions, arranged 
in haphazard, vaguely fascicular or storiform patterns (Figs. 3, 4). It has been reported that spindle cells 
predominated in 72 percent of AFX cases (Mirza B and Weedon D, 2005). Multinucleated giant tumor 
cells are scattered. The nuclei of the lesion may be hyperchromatic and multilobulated. In general, 
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numerous mitotic ﬁ  gures, including atypical ones, 
can be seen (Enzinger FM and Weiss SW, 2001; 
Fretzin DF and Helwig EB, 1973) (Fig. 5). Some 
cells of the lesion may contain vacuolated and 
lipid-containing cytoplasm similar to xanthoma. 
This provided the origins for the name of atypical 
“xanthoma” (Dettrick A and Strutton G, 2006) 
(Fig. 6). Solar elastosis associated with ultraviolet 
(UV)-radiation has been commonly observed 
(Fretzin DF and Helwig EB, 1973; Sakamoto A 
et al. 2001a). Appendage involvement within the 
lesion, which is suggestive of undestroyed adnexal 
structures, is frequently seen (Sakamoto A et al. 
2002) (Fig. 7). In addition to the classical AFX 
features, there have been reports of rare variants, 
including clear cells, osteoclastic giant cells, pig-
mented, osteoid, chondroid or granular cells and 
plaque-like cells (Crowson AN et al. 2002; 
Dettrick A and Strutton G, 2006; Fretzin DF and 
Helwig EB, 1973; Weedon D and Strutton G, 
2002). Cases of AFX with prominent sclerosis and 
hyalinization have been also reported (Bruecks AK 
et al. 2003).
Since the initial description of AFX, the lesion 
has been a source of much controversy. Because of 
the histological similarity between AFX and malig-
nant ﬁ  brous histiocytoma (MFH), AFX has been 
commonly regarded as a superﬁ  cial variant of MFH 
(Enzinger FM and Weiss SW, 2001). MFH is one 
of the most common sarcomas occurring deep 
within soft tissue (Enzinger FM and Weiss SW, 
2001). Most AFX cases (80%) are restricted to the 
reticular dermis. The lesion may extend into the 
upper one-third of the subcutaneous adipose tissue 
(Mirza B and Weedon D, 2005). Currently, AFX is 
considered to be different from MFH. Size and 
depth are important in the differentiation between 
AFX and MFH. If a tumor extensively involves the 
subcutis, penetrates the fascia and muscle, or dis-
plays necrosis or perineural and vascular invasion, 
it should be diagnosed as MFH (Enzinger FM and 
Weiss SW, 2001). Extension into deeper structures 
like the parotid gland has been reported (Skoulas 
IG et al. 2001). However, it may be better to char-
acterize such cases as MFH (Fish FS, 1996; Sankar 
NM et al. 1998). Previously reported cases of AFX 
may need to be reviewed carefully for a more pre-
cise diagnosis based on the current clinical and 
histologic criteria.
When AFX is less pleomorphic, it is indistin-
guishable from leiomyosarcoma (Calonje et al. 
1993). Histologically, being different from AFX, 
leiomyosarcoma has typically distinct fascicles 
containing cells with characteristic blunt-ended 
nuclei, and cytoplasmic glycogen is often abundant 
(Enzinger FM and Weiss SW, 2001). Dermatoﬁ  -
brosarcoma protuberans (DFSP) is another 
differential diagnosis from AFX. DFSP is a nodu-
lar cutaneous tumor and it has been considered as 
a fibroblastic, histiocytic and neural tumor. 
Microscopically, the main portion of DFSP is 
composed of a uniform population of slender 
ﬁ  broblasts arranged in a distinct, often monotonous 
storiform pattern. CD34 is expressed on hemato-
poietic stem cells and on vascular endothelial cells 
and it has been reported to be a marker of DFSP 
(Enzinger FM and Weiss SW, 2001), while the 
expression of CD34 is absent in AFX (Krustrup D 
et al. 2006).
Besides MFH and leiomyosarcoma, the major 
differential diagnosis includes pleomorphic and 
spindled variant of squamous carcinoma and 
malignant melanoma. Basal cell carcinoma 
and keratoacanthoma are also differential diagno-
ses. Histologically, in the differentiation between 
AFX and squamous cell carcinoma, there is neither 
junctional activity nor focal epithelial differentia-
tion in AFX (Enzinger FM and Weiss SW, 2001). 
In a case of clear cell variant of AFX, additional 
differential diagnoses should include clear cell 
sarcoma (malignant melanoma of soft parts), 
Figure 1. The facial lesion is protuberant and ulcerative, bleeding 
easily.
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balloon cell melanoma, metastatic renal cell 
carcinoma, sebaceous carcinoma and clear cell 
hidradenocarcinoma (Cai JP and Randall B, 2006; 
Crowson AN et al. 2002; Kao GF et al. 1992). 
Similarly, granular cell variant of AFX may need 
to be differentiated from granular cell tumor, 
including its malignant counterpart (Rudisaile SN 
et al. 2005).
Differential Diagnosis in Terms 
of Immunohistochemistry
Making a diagnosis of AFX is challenging and the 
diagnosis of AFX should be made by exclusion of 
the differential diagnoses. Combined immunohis-
tochemical markers are necessary for a deﬁ  nitive 
diagnosis (Table 1) (Hartel PH et al. 2006; 
Kanitakis J et al. 2000; Krustrup D et al. 2006). 
Absent immunostaining for cytokeratins, S100 and 
HMB45 in AFX is helpful for excluding both 
squamous cell carcinoma and malignant melanoma 
(Hultgren TL and DiMaio DJ, 2007; Mirza B and 
Weedon D, 2005). Cytokeratins are epithelial 
markers and they are positive for squamous cell 
carcinoma. S100 protein is widely used as a 
Schwann cell marker and it is also positive for 
malignant melanoma. HMB45 and MART-1 are 
melanocyte-speciﬁ  c markers, and these antibodies 
recognize gp100 and PMel17, respectively (Smith-
Zagone MJ et al. 2004). However, it should be 
remembered that some poorly differentiated squa-
mous cell carcinomas may not express cytokeratin, 
and S100 and HMB45 are not detectable in all 
malignant melanoma cases (Lodding P et al. 1990; 
Wick MR et al. 1988). Furthermore, dendritic cells 
within AFX may express S100 (Longacre TA et al. 
1993; Ricci A Jr et al. 1988; Winkelmann RK and 
Peters MS, 1985). Focal HMB45 and MART-1 
expression in the giant cells of an AFX has been 
reported (Smith-Zagone MJ et al. 2004).
CD10, or the common acute lymphoblastic 
leukaemia antigen (CALLA), is a cell-surface neu-
tral endopeptidase which is expressed by lymphoid 
precursor cells and by B lymphoid cells of germinal 
center origin (Ritz J et al. 1980). CD10 is reported 
to be a useful marker for AFX, because of its high 
positivity rate (95%–100%) (Mirza B and Weedon D, 
2005; Sakamoto A et al. 2002; Weedon D et al. 
2005). Although one-third of malignant melanoma 
cases have been reported to be positive for CD10, 
the staining was less intense and tended to accu-
mulate within the surrounding stroma (Hultgren TL 
and DiMaio DJ, 2007). On the other hand, about 
half the cases of squamous cell carcinoma showed 
Figure 2. Atypical ﬁ  broxanthoma shows an exophytic cellular nodule with ulceration of the overlying epidermis. The nodule is restricted to 
the reticular dermis. (Hematoxylin and eosin, original magniﬁ  cation, x8).
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positivity for CD10, but the staining was also weak 
in most of the cases, involving less than 25% of 
cells (Hultgren TL and DiMaio DJ, 2007).
CD99, or p30/32, is a glycoprotein product of 
the MIC2 gene. It was originally utilized in immu-
nohistochemistry as a unique marker for Ewing 
sarcoma. CD99 has been reported to be a useful 
marker of AFX, but the positivity rate for CD99 
has been reported to vary between 35% (Mirza B 
and Weedon D, 2005) and 73% (Monteagudo C 
et al. 2002) of AFX cases, although none of the 
squamous cell carcinoma cases have been reported 
to be positive for CD99 (Monteagudo C et al. 
2002). However, it has been revealed that 10% 
(Monteagudo C et al. 2002) and 60% (Wilkerson 
AE et al. 2006) of malignant melanomas show 
positive staining for CD99.
Procollagen is secreted by ﬁ  broblasts into the 
extracellular matrix, where it is cleaved to form 
collagen. Procollagen-1 staining was strongly 
positive in 87% of AFX cases (Jensen K et al. 2004). 
On the other hand, positive staining in the tumor 
cells was observed in about one-third of the desmo-
plastic squamous cell carcinomas and desmoplastic 
malignant melanomas (Jensen K et al. 2004).
Taken together, these ﬁ  ndings suggest that there 
is no speciﬁ  c sole immunohistochemical marker 
of AFX that would help differentiate it from squa-
mous cell carcinoma and malignant melanoma. A 
combination of immunohistochemical markers is 
important to make a clear diagnosis of AFX.
AFX is a Unique Entity, 
in Comparison to MFH
AFX, as well as MFH, is a ﬁ  brohistiocytic lesion 
with myoﬁ  broblastic differentiation (Sakamoto 
A et al. 2002). A histiocytic/macrophage marker, 
Figure 3. Atypical ﬁ  broxanthoma shows a proliferation of atypical spindled cells in a haphazard or disorderly pattern. (Hematoxylin and eosin, 
original magniﬁ  cation, x180).
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Figure 4. Atypical ﬁ  broxanthoma shows plump pleomorphic epithelioid cells. (Hematoxylin and eosin, original magniﬁ  cation, x180).
CD68, is positive in more than half of all AFX 
cases (Hultgren TL and DiMaio DJ, 2007; 
Smith-Zagone MJ et al. 2004). However, CD68 
is also detectable in 86% of malignant melanoma 
cases (Pernick NL et al. 1999). As seen in MFH, 
AFX has immunoreactivities for several 
myogenic/myoﬁ  broblastic markers comprising 
desmin, alpha-smooth muscle actin and muscle-
speciﬁ  c actin. Calponin and h-caldesmon are 
cytoskeleton-associated actin-binding proteins. 
They have been reported to be more speciﬁ  c 
myogenic markers. Positive or negative expres-
sion for calponin and negative expression for 
h-caldesmon in AFX is useful for distinguishing 
it from leimyosarcoma, which has smooth mus-
cle differentiation characterized by positive ﬁ  nd-
ings for calponin and h-caldesmon, but such 
expression is shared by both AFX and MFH 
(Sakamoto A et al. 2002).
A high percentage of CD10 expression in AFX 
could be a marker from leiomyosarcoma, in which 
about half the cases of leiomyosarcomas are posi-
tive for CD10 (Sakamoto A et al. 2007). On the 
other hand, CD10 has been expressed in almost all 
the cases of MFH, as well as AFX (Sakamoto A 
et al. 2007; Weedon D et al. 2005). However, the 
number of AFX cases with moderate/strong or 
diffuse immunoreactivity for CD99 is signiﬁ  cantly 
larger than that of MFH cases (Hartel PH et al. 
2006). On the other hand, the LN-2 (CD74) antigen 
is the MHC-II complex and it is found on B cells, 
macrophages, monocytes, Reed-Sternberg cells 
and other B-cell proliferations. AFX and MFH may 
have been differentiated based upon positivity for 
CD74, in which reduced immunoexpression for 
CD74 in AFX is characterized compared to that in 
MFH (Lazova R et al. 1997). Further examination 
will be necessary in order to conﬁ  rm the reliability 
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of CD74 as a marker with which to differentiate 
between AFX and MFH (Ly H et al. 2004).
It seems that AFX and MFH share histological 
and immunological features. There are also simi-
larities between the two lesions in terms of a high 
proliferation rate in the case of the proliferation 
markers of PCNA and MIB-1 (Oshiro Y et al. 1995; 
Sakamoto A et al. 2007), as well as similarities 
regarding apoptotic counts and bcl2 expression, 
which is a regulator protein for apoptosis 
(Westermann FN et al. 1997). However, from a 
molecular aspect, AFX is characterized by a diploid 
pattern, while the majority of chromosomal changes 
in MFH are of an aneuploid pattern (Oshiro Y et al. 
1995; Worrell JT et al. 1993). H-, K-, and N-ras gene 
mutations are not present in AFX, whereas MFH 
has H- and K-ras gene mutations, although only a 
small number of cases was studied (Sakamoto A 
et al. 2001b). In a comparison between MFH and 
leiomyosarcoma, a previous report supported the 
opinion that MFH may represent a morphological 
pathway in tumor progression of leiomyosarcoma 
according to the same shared chromosome abnor-
mality (Sabah M et al. 2005). It is also possible that 
AFX and MFH share the same pathway which 
determines their morphology, but that AFX and 
MFH may have different pathways of biological 
behavior which determine their clinical behavior. In 
a previous report, comparative genomic hybridiza-
tion (CGH) analysis demonstrated similarities 
between AFX and undifferentiated pleomorphic 
sarcoma, or MFH. The CGH data demonstrated that 
genetic alterations on chromosomes 9p and 13q 
seem to suggest a common pathogenetic pathway 
(Mihic-Probst D et al. 2004).
Molecular Mechanism
AFX typically occurs on the head and neck of sun-
exposed skin. This fact has long suggested a role 
Figure 5. Atypical ﬁ  broxanthoma. Atypical mitosis can be observed. (Hematoxylin and eosin, original magniﬁ  cation, x200).
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Figure 6. Atypical ﬁ  broxanthoma. Frequent xanthoma cells are visible. (Hematoxylin and eosin, original magniﬁ  cation, x200). 
for sun exposure in the tumorigenesis of AFX. UV 
radiation from sunlight is an important risk factor 
for skin cancer (Aragane Y et al. 1998). DNA dam-
age caused by UV is primarily repaired by the 
nucleotide excision repair (NER) pathway. The 
tumor suppressor protein p53 is a transcriptional 
activator and it is involved in cell cycle control, 
apoptosis and genome instability. p53 also plays a 
direct role in NER (Lee S et al. 1995; Reed M 
et al. 1995). The predominant mutation patterns of 
C-T transitions and CC-TT double transitions at 
dipyrimidine sites in the p53 gene are considered 
to be characterized by UV radiation (Brash DE 
et al. 1991; Miller JH, 1985), thereby suggesting 
a central role of UV radiation in the development 
of AFX (Dei Tos et al. 1994). The association 
between decreased DNA repair ability and AFX 
may be supported by a report showing that patients 
with xeroderma pigmentosum had AFX, and it is 
known that xeroderma pigmentosum is related to 
DNA repair defects (Dilek FH et al. 2000; Weedon 
D and Strutton G, 2002).
The formation of DNA photoproducts by UV 
radiation is reported to be responsible for the 
development of skin cancer (Pfeifer GP, 1997). 
Among these photoproducts, cyclobutane pyrimi-
dine dimers (CPDs) and pyrimidine-pyrimidone 
(6–4) photoproducts (64PPs) are important as they 
are involved in mutagenesis and carcinogenesis 
(Hart RW et al. 1977; Moan J and Peak MJ, 1989). 
DNA photoproducts are removed by NER. DNA 
photoproducts can interfere with the binding of 
several important cell-cycle regulatory and DNA 
damage-responsive transcription factors (Tommasi 
S et al. 1996). It has been reported that the accu-
mulation of DNA photoproducts may play an 
important role in the pathogenesis of AFX 
(Sakamoto A et al. 2001a).
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Figure 7. Atypical ﬁ  broxanthoma. Appendage involvement within the lesion can be observed. (Hematoxylin and eosin, original magniﬁ  cation, 
x100).
Table 1. Immunohistochemical proﬁ  les of AFX and its differentiations.
Antibody Marker  AFX  MFH  LMS  SCC  MM  DFSP
Vimentin Mesenchymum  +  +  +  −  +  +
Cytokeratin Epithelium  −  −  −  +  −  −
EMA Epithelium  −  −  −  +  −  −
S100 Schwann  cell  −  −  −  −  +  −
HMB45 Melanocyte  −  −  −  −  +  −
MART-1 Melanocyte  −  −  −  −  +  −
SMA Myocyte/myoﬁ  broblast  +/−  +/−  +  −  −  +/−
Desmin Myocyte/myoﬁ  broblast  +/−  +/−  +  −  −  +/−
Calponin Myocyte/myoﬁ  broblast  +/−  +/−  +  −  −  −
h-Caldesmon Myocyte  −  −  +  −  −  −
CD10 (CALLA)  Lymphoid precursor  +  +  +/−  +/−  +/−  +/−
CD34 Endothelium  −  −  −  −  −  +
CD68 Histiocyte/macrophage  +  +  −  −  −  −
CD74 (LN-2)  MHC-II complex  +/−  + N  N  N  +/−
CD99 (p30/32)  MIC2 gene product  +/−  +/−  −*  −  +/−  −*
Procollagen-1 Procollagen  +  +*  +/−  +/−  +/−  +
Abbreviations: AFX: atypical ﬁ  broxanthoma; MFH: malignant ﬁ  brous histiocytoma; LMS: leiomyosarcoma; SCC: squamous cell carcinoma; 
MM: malignant melanoma; DFSP: dermatoﬁ  brosarcoma protuberans; EMA: epithelial membrane antigen; SMA: smooth muscle actin; CALLA: 
common acute lymphoblastic leukaemia antigen; N: not reported; +: positive in most cases; +/−: positive but not always; −: negative in most 
cases; *: small number of cases has been assessed.
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Prognosis and Treatment
There are no clear recommendations regarding the 
treatment of AFX (Seavolt M and McCall M, 
2006). However, AFX is usually treated surgically, 
and the recurrence rate has been reported to range 
between 5% (Weedon D and Strutton G, 2002) and 
10% (Fretzin DF and Helwig EB, 1973; Giuffrida 
TJ et al. 2004). Multiple local recurrence has 
rarely been reported (Jacobs DS et al. 1975). 
Metastases are uncommon and occur in approxi-
mately 1% of reported cases (Davis JL et al. 1997; 
Grosso M et al. 1987). However, no recurrence or 
metastasis was observed in 89 AFX lesions (Mirza 
B and Weedon D, 2005). Features associated with 
metastasis include recurrence, vascular invasion, 
large tumor, deep tissue invasion and tumor 
necrosis (Giuffrida TJ et al. 2004; Helwig EB and 
May D, 1986). It has been analyzed that these 
locally invasive and/or metastasizing lesions may 
have initially been MFH, squamous cell carcinoma 
or malignant melanoma, rather than AFX (Giuffrida 
TJ et al. 2004; Starink TH et al. 1977).
As for surgical margin, wide excision with 1 
cm margins has been recommended in the past 
(Giuffrida TJ et al. 2004). However, there have 
been reports of Mohs microsurgery treatment for 
AFX with favorable results (Brown MD and 
Swanson NA, 1989; Davis JL et al. 1997; Huether 
MJ et al. 2001; Zalla MJ et al. 1997). Mohs 
microsurgery is an operation that removes the 
neoplasm and as little of the normal tissue as 
possible. During the surgery, a microscope is 
used to look at the neoplastic area in order to 
make sure that all of the neoplastic cells have 
been removed.
Conclusion
AFX is now believed to be a benign lesion centered 
in the dermis in the sun-exposed skin of the elderly 
or children with xeroderma pigmentosum or other 
conditions with defective DNA repair. Decreased 
DNA repair ability might be associated as a patho-
genesis in AFX, although further examinations are 
necessary, in order to ascertain whether this is 
actually true or not. Making a diagnosis of AFX is 
challenging. The diagnosis should be made only 
after applying the stringent histological criteria and 
a broad panel of immunostains. AFX is thought to 
be a different lesion from MFH. AFX and MFH 
might share the same pathway which determines 
the morphology, but they may have different 
pathways which determine biological activity in a 
tumor-speciﬁ  c manner.
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